BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37287020)

  • 21. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
    Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
    Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    Sumodhee S; Bondiau PY; Poudenx M; Cohen C; Naghavi AO; Padovani B; Maneval D; Gal J; Leysalle A; Ghalloussi H; Otto J; Doyen J
    BMC Cancer; 2019 Apr; 19(1):305. PubMed ID: 30943943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?
    Chen H; Louie AV
    Curr Treat Options Oncol; 2016 Jun; 17(6):27. PubMed ID: 27098533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
    Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
    Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
    Moding EJ; Liang R; Lartey FM; Maxim PG; Sung A; Diehn M; Loo BW; Gensheimer MF
    Clin Lung Cancer; 2019 Nov; 20(6):461-468.e2. PubMed ID: 31377143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
    JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis.
    Lee TH; Kim DY; Wu HG; Lee JH; Kim HJ
    Radiat Oncol; 2021 Nov; 16(1):222. PubMed ID: 34794471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
    Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
    Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
    Hayashi K; Suzuki O; Shiomi H; Nakai M; Fujiwara K; Nakanishi E; Tatekawa S; Hirata T; Tamari K; Hirata H; Funaki S; Seo Y; Takeda Y; Isohashi F; Shintani Y; Ogawa K
    Anticancer Res; 2022 Jan; 42(1):321-327. PubMed ID: 34969740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
    Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
    Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.